A concise, high-yield guide to cholesterol-lowering therapies—statins, Zetia, PCSK9 inhibitors, bempedoic acid, berberine, ...

Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...

Cholesterol-related heart disease remains the leading cause of death worldwide, and while doctors have more tools than ever ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...

Share on Pinterest A new study explores the cholesterol-lowering effects of a new drug called enlicitide. Nicole Mason/Stocksy A new study investigates the cholesterol-lowering effects of an ...

Researchers say newly identified cholesterol control pathway is completely separate from anything targeted by existing drugs.

This depletion process ultimately relies on an enzyme called cathepsin A (CTSA). The researchers found that blocking CTSA ...

Some types of cancer have a relentless appetite for the metabolite cholesterol, using as much as they can access to accelerate their growth beyond the capabilities of normal cells. Research by ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A once-daily oral PCSK9 inhibitor reduced LDL in ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...